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The drive for improved regulatory systems and the establishment of a more effective
regulatory framework in South Africa has been evident for the past two decades
but despite political intentions and legislative revisions success has been limited
to date. Efforts to address the increasing volume of applications that have been
received have to date failed and resources have been stretched to capacity resulting
in the development of a significant backlog and extended timelines for product
registration. The promulgation of the recently amended Medicines and Related
Substance Act of 1965 triggered the establishment of the South African Health Products
Regulatory Authority (SAHPRA) as a separate juristic person outside of the National
Department of Health to replace the former medicine regulatory authority the Medicines
Control Council (MCC). The aim of this review is to provide the historical context
supporting the new regulatory environment in South Africa and the transition from
the MCC to SAHPRA. Key recommendations to SAHPRA to ensure the full potential
of the new regulatory environment in South Africa include: establishing a quality
management system to safeguard accountability, consistency and transparency and
to streamline the implementation of good review practices including quality decision-
making practices and benefit-risk assessment; the measurement and monitoring of
regulatory performance, targets for overall approval time and key review milestones to
instill a culture of accurate metrics collection and measurement of key performance
indicators and their continuous improvement and the employment of a risk-based
approach to the evaluation of medical products and codify the use of facilitated
regulatory pathways in policy and culture. The application of a risk-based approach
to regulatory review commensurate with a product’s risk to patients will facilitate the
application of increased resources for pharmacovigilance activities and to support the
reliance and recognition of reference agencies.
Keywords: South African Health Products Regulatory Authority (SAHPRA), Medicines Control Council, MCC,
legislation, risk-based review
Abbreviations: CEO, Chief Executive Officer; EDMS, electronic document management system; FRPs, facilitated regulatory
pathways; GMP, good manufacturing practice; GRevP, good review practice; GRP, good regulatory practice; ICT, Information
and Communication Technology; MCC, Medicines Control Council; NCEs, new chemical entities; NRAs, national regulatory
authorities; PFMA, Public Finance Management Act; PMA, Pharmaceutical Manufacturers Association; QMS, quality
management system; SAHPRA, South African Health Products Regulatory Authority; SAMMDRA, South African Medicines
and Medical Devices Regulatory Authority; TORS, Technical Operations and Regulatory Strategy; WHO, World Health
Organization.
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INTRODUCTION
Ensuring effective medicine regulation through the strengthening
of regulatory systems and improvement of regulatory
performance has become a priority for both NRAs and
governments worldwide. With the support of government NRAs
are responsible for protecting and promoting public health,
implementing rigorous regulatory standards and maintaining an
assured supply of medical products that are safe, effective and
of good quality (Rägo et al., 2008; Ndomondo-Sigonda et al.,
2017; World Health Organization [WHO], 2018). Despite the
critical role that NRAs play within national healthcare systems
the importance of medical product regulation often goes “under-
recognized” and is often “under-funded” (Rägo et al., 2008). The
WHO has indicated that “at least 30% of NRAs do not have the
capacity to perform core regulatory functions” (Rägo et al., 2008)
and “without adequate financial support regulatory authorities
do not have the necessary resources to sustain effective regulation
of medical products” (World Health Organization [WHO],
2003).
Global trends toward increased pressure on NRAs of all
sizes and capacity due to the increased volumes of applications
received, the complexity of the submissions and the increased
number of categories of medical products have been noted
(World Health Organization [WHO], 2014a). These trends
and statistics resonate with many NRAs in low- and middle-
income countries that have historically been faced with resource
constraints (World Health Organization [WHO], 2014b) and
that have not participated in global harmonization initiatives
or development programs aimed at strengthening regulatory
systems (Preston et al., 2012). Efforts to address the challenges
faced by NRAs in resource-limited settings have focused on
identifying and performing core regulatory functions that
have to be undertaken directly by NRAs to meet country or
regional needs (Ward, 2014; World Health Organization [WHO],
2014b). NRAs have also been encouraged by the WHO to
consider regulatory convergence and to collaborate with and
recognize work done by other regulators to ease the regulatory
burden (Ward, 2014; World Health Organization [WHO],
2014b).
Resolution WHA67.20 emanating from the Sixty-seventh
World Health Assembly in 2014 identified the need for effective
regulatory systems and highlighted that “inefficient regulatory
systems create barriers for access to safe, effective and quality
medical products” (World Health Assembly, 2014). The drive for
improved regulatory systems and the establishment of a more
effective regulatory framework in South Africa has been evident
for the past two decades but despite political intentions and
legislative revisions success has been limited to date.
It is suggested that while multi-factorial elements have
resulted in a backlog in medicines registration significant pro-
access policies compounded by legislative requirements for the
expedited review of medicines on the Essential Medicines List,
most of which are generics, may be at the root of the problem
(Leng et al., 2015). Efforts to address the increasing volume
of applications that have been received have to date failed
and resources have been stretched to capacity resulting in the
development of a significant backlog and extended timelines for
product registration. The median approval times for fast track
applications approved by the MCC in 2015, 2016, and 2017 were
1218, 921, and 609 calendar days, respectively (Keyter et al.,
2018). There was no target time set for the overall review time
of NCEs and the median approval times for NCE marketing
authorization applications approved in 2015, 2016, and 2017 were
1161, 1678, and 1422 calendar days, respectively (Keyter et al.,
2018). These data demonstrate that the MCC was not able to
achieve the target timelines of 250 calendar days set for fast track
applications nor meet the targets in 2015, 2016, and 2017 for the
key milestones within the regulatory review process (Keyter et al.,
2018).
Pharmaceutical companies, private clinical research
organizations, academic clinical research groups and civil
society organizations have complained that delays and the
backlog in medicines registration were harming patients’ access
to affordable medicines (Leng et al., 2015). “Prior to 2005 the
number of applications received and the number of registration
certificates issued were in equilibrium, however, from 2005 the
number of applications submitted more than doubled whereas
the number of certificates issued remained approximately the
same” (Leng et al., 2015). The South African NRA has a historical
average of receiving approximately 4700 applications per year but
has demonstrated that it can only process approximately 2550
applications per annum (South African Health Products
Regulatory Authority [SAHPRA], 2018). SAHPRA has
inherited a backlog of approximately 16 000 applications
that includes all applications submitted up to 31 January
2018 which are yet to receive final approval (South African
Health Products Regulatory Authority [SAHPRA], 2018).
The SAHPRA Board aims to clear the backlog within the
next 2 years and with more than half of new registration
applications being at least 5 years old industry has been
requested to “opt-in” for applications submitted in 2013 or
earlier. Submissions within the backlog need to be consolidated,
updated and resubmitted to ensure that submissions requiring
evaluation reflect current data (South African Health Products
Regulatory Authority [SAHPRA], 2018). Applications will
be segmented and prioritized according to public health
priorities (South African Health Products Regulatory Authority
[SAHPRA], 2018). SAHPRA will operationalize reliance models
for product review supported by optimal staffing solutions,
implementation of a digitally powered approach to evaluation,
effective change management and improved transparency and
accountability (South African Health Products Regulatory
Authority [SAHPRA], 2018).
The promulgation of the recently amended Medicines and
Related Substance Act, 1965 (Act 101 of 1965) hereafter referred
to as the Medicines Act triggered the establishment of the
SAHPRA as a separate juristic person outside of the National
Department of Health to replace the former medicine regulatory
authority the MCC. The amended Medicines Act saw the scope
of the Authority’s mandate extended to make provision for
the regulatory oversight of medical devices and complementary
medicines in South Africa and to make provision for the
Authority to establish and strengthen collaborative initiatives
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with any other regulatory authorities or institutions (Republic of
South Africa, 2017).
The aim of this review is to provide the historical context
supporting the new regulatory environment in South Africa and
the transition from the MCC to SAHPRA.
THE MEDICINES CONTROL COUNCIL
Prior to the establishment of SAHPRA in February 2018
the MCC was the national medicines regulatory authority of
South Africa responsible in terms of the Act to provide for
the monitoring, evaluation, regulation, investigation, inspection,
registration and control of human and veterinary medicines,
scheduled substances, clinical trials and related matters in the
public interest. The statutory obligations of the MCC were to
ensure that medicines that were available in South Africa met
the required standards of quality, safety, and efficacy (Medicines
Control Council [MCC], 2006).
Organizational Structure
The MCC was a statutory body appointed by the Minister of
Health consisting of not more than 24 members including
the chairs of the expert committees. In addition the council
appointed external experts to serve on various expert committees
overseeing medicine registration, regulation and control
functions. Overall there were 11 active expert committees
including the Biological Medicines, Clinical, Clinical Trials,
Complementary Medicines, GxP, Legal, Medical Devices, Names
& Scheduling, Pharmaceutical & Analytical, Pharmacovigilance
and Veterinary Clinical Committees (Medicines Control
Council [MCC], 2017). The skills of the members of council
and its committees were written into law and included
expertise in toxicology and medicine safety, basic and clinical
pharmacology, biotechnology, pharmaceutics, internal medicine,
virology, pharmaceutical chemistry, neonatology, pediatrics,
immunology, veterinary science, complementary medicines and
law (Medicines Control Council [MCC], 2017).
The Office of the Registrar served as the Executive Secretary
to the MCC and provided administrative and technical support
to Council and its activities. The Office of the Registrar was
a Chief Directorate within the National Department of Health
known as the Cluster: Food Control, Pharmaceutical Trade and
Product Regulation. There were four Directorates within the
Cluster namely Operations and Administration, Inspectorate
and Law Enforcement, Medicines Evaluation and Research
and Clinical Evaluation and Trials. The staff complement
of the Cluster included doctors, pharmacists, veterinarians,
scientists and administrative staff (Medicines Control Council
[MCC], 2017). The MCC organizational structure is depicted in
Figure 1 (South African Health Products Regulatory Authority
[SAHPRA], 2016).
Regulatory Review Process
The registration of medicines in South Africa is governed by the
provisions and requirements of the Medicines Act including the
regulations and the published guidelines. Legislative frameworks
require that medicines including NCEs, multisource/generic
medicines, biological medicines, complementary medicines and
veterinary medicines are evaluated by the NRA prior to
marketing of the product. Applicants are required to submit
technical dossiers to demonstrate the quality, safety, and efficacy
of such medicines intended for sale in South Africa. The
confidentiality of information submitted to the NRA is governed
by Section 34 of the Medicines Act regarding the preservation of
secrecy. The regulatory review process of the MCC is presented in
Figure 2 and provides a simple representation of the review and
authorization of applications that are approved in the regulatory
review cycle.
The NRA made use of both internal and external expertise
to evaluate applications for the registration of medicines. A full
review of the safety, quality, and efficacy data, together with
the assessment reports prepared by reviewers were considered
by the various expert committees to make recommendations
on the approval of the proprietary name of the product, the
allocation of a scheduling status for the active pharmaceutical
ingredient and the evaluation of the GMP status of the applicant,
the manufacturer of the active pharmaceutical ingredient, the
manufacturer of the finished pharmaceutical product, the packer
and the quality control laboratory. The final decision for
authorization or refusal was made by the MCC.
History of Enabling Legislation
The introduction of the regulation of medicines in South Africa
was initiated in the 1960s when the National Department of
Health appointed the Snyman Commission to investigate the
high cost of medicines and medical services in South Africa
(Snyman, 1965). The report of the Commission of Inquiry
recommended at the time that medicines be controlled in terms
of their “purity, safety and therapeutic efficacy” (Gouws, 2003).
These recommendations resulted in the promulgation of the
Drugs Control Act, 1965 (Act 101 of 1965) and the establishment
of the Drugs Control Council responsible for the control of
medicines for human use (Gouws, 2003). The introduction of a
registration procedure in 1968 meant that all medicines intended
for sale in South Africa were evaluated and approved by the Drugs
Control Council prior to entering the market. Medicines available
on the market prior to 1968 were initially exempt from these
requirements and were referred to as “old medicines” (Gouws,
2003). Over the next three decades the legislative framework and
regulatory requirements were amended several times to reflect
the intentions of the regulatory authority as it strived toward
improved control of medicines in South Africa. Some of the
important amendments made to the principal Act, the Medicines
and Related Substances Act, 1965 (Act 101 of 1965) are listed in
Table 1 (Gouws, 2003) and the historic projects and legislative
changes are noted in Table 2.
The Amendment Act, 1997 (Act 90 of 1997) was the first
legislative amendment to be made to the principal Act following
the change of government in South Africa after the general
elections held in 1994 (Gouws, 2003). With this change came
the adoption of a program for health reform and the launch of
the National Drug Policy (Gouws, 2003). The Amendment Act,
1997 (Act 90 of 1997) was promulgated in 1997 and Section
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FIGURE 1 | Organizational structure of the Medicines Control Council.
FIGURE 2 | Regulatory review process of the Medicines Control Council.
15C specifically was the subject of a legal challenge by the PMA
which prevented the implementation of the Amendment Act,
1997 (Act 90 of 1997) until 2003 (Pharmaceutical Manufacturers
Association [PMA], 1998). The then Minister of Health,
Nkosazana Dlamini-Zuma appointed an advisory panel to review
the medicine regulatory environment in South Africa (Dukes
et al., 1998). In December 1998 a report titled “Operational
and Financial Review - Discussion Draft” prepared by KPMG
also endorsed the restructuring of the MCC with the aim of
improving operational efficiencies. On the recommendation of
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TABLE 1 | Amendments to Drug Control Act 1965.
Amendment Number Change
Amendment Act No 29 of 1968 Drugs that were subjected to registration were
defined
Categories for the classification of these drugs
were defined
Amendment Act No 88 of 1970
Amendment Act No 95 of 1971
Made provision for the control of advertising of
drugs.
Amendment Act No 65 of 1974 The term “drug” was replaced with “medicine”
The Drugs Control Council was changed to the
Medicines Control
Council
The constitution of the Medicines Control
Council, remuneration of the Council members
and the appointment of the Committees of
Council and a Medicines Control Appeal Board
was defined.
Amendment Act No 17 of 1979 The mandate of the Act was extended to
include the regulatory oversight of veterinary
medicines, including the registration, labeling
and advertising thereof.
Amendment Act No 94 of 1991 The powers, functions and constitution of the
Council were defined
The establishment of the Medicines Control
Appeal Board was repealed
Provisions for an alternative appeal procedure
against the decision of the Council were
defined.
Amendment Act No 90 of 1997 The MCC was established as a juristic person
Members of the Council or the Committees
were required to declare commercial interests
related to the pharmaceutical or health care
industry
The members of the Executive Committee of
the Council, were to be appointed subject to
the approval by the Minister of Health
Conditions prohibiting the sale of any medicine,
which were subject to registration, and which
were not registered, were defined
Provision for expedited registration of essential
medicines
Re-registration of medicines every 5 years
Provisions for compulsory licensing and parallel
importation
Provisions to enable generic substitution were
defined
A Pricing Committee for medicines was
established
The process of appeal against a decision of the
Director-General of Health was defined
Provision was made for acquiring of additional
funds by the Council
The powers of the Minister of Health to make
regulations pertaining to the Medicines Act
were further defined.
Amendment Act 59 of 2002 Provision was made for the appointment of
Deputy Registrars
the term of office of the Pricing Committee
members was defined
Regulations relating to the marketing of
medicines was defined and
Repeal of the SAMMDRA Act.
the ministerial advisory panel a new Amendment Act (Republic
of South Africa, 1998) establishing the SAMMDRA to replace
the MCC was passed by Parliament. The SAMMDRA Act was
promulgated prematurely without the necessary Regulations
and was subsequently set aside (Pharmaceutical Manufacturers
Association [PMA], 2000).
In late 2007 yet another decision was taken to restructure
the MCC by establishing a new authority as a public entity
outside of the National Department of Health. A report on the
restructuring of the MCC was presented by a Ministerial Task
Team led by Professor Green-Thompson who was appointed as
a Special Advisor to the Minister of Health, Manto Tshabalala-
Msimang. (South African Health Products Regulatory Authority
[SAHPRA], 2016). The Green-Thompson Report recommended
the establishment of a new NRA to replace the MCC referred
to as SAHPRA and emphasized the need for international and
regional harmonization to support reliance and recognition
frameworks with other regulatory authorities (Green Thompson,
2008). The report amongst others recommended extending the
regulatory mandate of the authority to include medical devices
and highlighted the need to effect benefit-risk assessment of
medicines and quality decision-making principles to support
transparent regulatory decision-making (Green Thompson,
2008). Regulatory models of other NRAs were benchmarked
and a key recommendation from this report informed the
need for collection of metrics to facilitate the measurement
and monitoring of regulatory performance and the impact
of the proposed changes to the regulatory review process
(Green Thompson, 2008). The recommendations of the Green-
Thompson report resulted in a further amendment of the
principal Act and the Medicines Amendment Act, 2008 (Act
72 of 2008) was signed into law by then President Kgalema
Motlanthe in 2009 but not implemented (South African Health
Products Regulatory Authority [SAHPRA], 2016). The reason for
this was multi-factorial and included the need for strengthened
governance and certain transitional provisions.
A project team led by Dr Nicholas Crisp was appointed
in 2009 by the Minister of Health, Barbara Hogan to revive
legislative endeavors directed toward regulatory reform and
the establishment of an improved NRA (South African Health
Products Regulatory Authority [SAHPRA], 2016). The remit
of this project team was to develop the business case for
SAHPRA as well as the transitional mechanisms and the
identification of further legislative amendments. Through the
work of the project team further amendments were made to
the Medicines Amendment Act, 2008 (Act 72 of 2008) and
the Medicines and Related Substances Amendment Bill, 2012
was published for comment in March 2012 (South African
Health Products Regulatory Authority [SAHPRA], 2016). In
July 2012 the project team presented a draft business case for
the establishment of SAHPRA (South African Health Products
Regulatory Authority [SAHPRA], 2012). The business case put
forward a motion to establish SAHPRA as a Schedule 3A
Public Entity to reinforce the political will to establish an NRA
with operational autonomy and accountability. The business
case defined an extended mandate for SAHPRA including the
regulatory oversight of food, complementary medicines, medical
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TABLE 2 | Historic Projects and Legislative Changes.
Timeline Initiated by Project Team Objective Recommendation Result
1960 South African National
Department of Health
Snyman Commission • Investigate the high cost of
medicines and medical
services in South Africa
• Medicines should be
controlled in terms of their
“purity, safety and
therapeutic efficacy”
• Promulgation of the Drugs
Control Act, 1965 (Act 101
of 1965)
• Establishment of the Drugs
Control Council
1998 Minister of Health,
Nkosazana
Dlamini-Zuma
Advisory Panel • Review the medicine
regulatory environment in
South Africa
• Endorsed the restructuring
of the MCC with the aim of
improving operational
efficiencies
• The new Amendment Act
establishing the
South African Medicines and
Medical Devices Regulatory
Authority (SAMMDRA) to
replace the MCC was
passed by Parliament
2007 Minister of Health,
Manto
Tshabalala-Msimang.
Ministerial Task Team
led by Professor
Green-Thompson
• Report on the restructuring
of the MCC
• The establishment of a new
NRA to replace the MCC
referred to as SAHPRA
• The need for international
and regional harmonization
• The need for collection of
metrics to facilitate the
measurement and
monitoring of regulatory
performance
• Further amendment of the
principal Act
• The Medicines Amendment
Act, 2008 was signed into
law by then President
Kgalema Motlanthe in 2009
but not implemented
2009 Minister of Health,
Barbara Hogan
Project team led by Dr
Nicholas Crisp
• Revive legislative endeavors
directed toward regulatory
reform
• Establishment of an
improved NRA
• Develop the business case
for SAHPRA
• Identification of further
legislative amendments
• Further amendment to the
Medicines Amendment Act,
2008
• The Medicines and Related
Substances Amendment Bill,
2012 was published for
comment in March 2012
2012 Director General of
Health, Malebona
Precious Matsoso,
Health Products
Technical Task Team
(HPTTT)
• Advise on the key legislative,
programmatic,
infrastructural, structural and
operational elements
required for the transition to
SAHPRA
• Benchmark regulatory
procedures in identified
technical and operational
areas
• Explore mechanisms for
information sharing and
systems to establish mutual
recognition for registration
requirements and product
approval
• Finalization of the Medicines
and Related Substances
Amendment Bill, 2012
• The new Medicines
Amendment Act, 2015 was
approved (January 2016)
• The draft SAHPRA business
case prepared by Dr Nicolas
Crisp was amended to
reflect current developments
and the key elements
required for the transition of
the MCC to SAHPRA
devices and radiation control. The report demonstrated historical
under-funding of the NRA linked with recommendations for
levying increased fees and motivated for “proactive remuneration
strategies” to attract and retain the expertise required to execute
the mandate of SAHPRA. It also expanded on the over-
reliance on paper-driven systems and the necessity for an
EDMS (South African Health Products Regulatory Authority
[SAHPRA], 2012).
The Director General of Health, Malebona Precious Matsoso,
also appointed a Health Products Technical Task Team (HPTTT)
in 2012 to consider the project team’s recommendations
and to advise further on the key legislative, programmatic,
infrastructural, structural and operational elements required for
the transition to SAHPRA (Health Products Technical Task
Team, 2014; Pharasi and Banoo, 2015). The HPTTT as part
of its mandate engaged several NRAs (the European Medicines
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Agency, U.S. Food and Drug Administration, Swissmedic, the
United Kingdom Medicines and Healthcare Products Regulatory
Agency and Australian Therapeutic Goods Administration) to
examine and benchmark regulatory procedures in identified
technical and operational areas as well as to explore mechanisms
for information sharing and systems to establish mutual
recognition for registration requirements and product approval.
These activities were also aimed at maximizing regulatory
capacity and operations under SAHPRA through understanding
the structure and functioning of these agencies in line with
international best practice standards. One of the outcomes of
the HPTTT work was the finalization of the Medicines and
Related Substances Amendment Bill, 2012 and its introduction
to Parliament for consideration. The new Medicines Amendment
Act, 2015 (Act 14 of 2015) was approved by the Parliament,
assented to by the President in December 2015 and published
in the Government Gazette in January 2016 (South African
Health Products Regulatory Authority [SAHPRA], 2016). The
draft SAHPRA business case prepared by Dr Nicolas Crisp
was further amended by the HPTTT to reflect current
developments and the key elements required for the transition
of the MCC to SAHPRA (South African Health Products
Regulatory Authority [SAHPRA], 2016). The amended business
case defined the preparation and operationalization of the
transition, directed the development of a new fee schedule
published in September 2015 to support the viability of the
new NRA, informed the development and publication of
the regulations for medical devices in December 2016 and
confirmed the withdrawal of food control from the regulatory
ambit of SAHPRA (South African Health Products Regulatory
Authority [SAHPRA], 2016). With the focus on financial
and operational considerations these transitional arrangements
overlooked the critical need for the review and improvement
of the regulatory review process of the NRA as recommended
in the Green-Thompson report. On the 1st June 2017 the
amendments to the principal Act were enacted via proclamation
of the Medicines and Related Substances Amendment Act,
2008 (Act 72 of 2008) read together with the Medicines
and Related Substances Amendment Act, 2015 (Act 14 of
2015).
THE SOUTH AFRICAN HEALTH
PRODUCTS REGULATORY AUTHORITY
In February 2017 SAHPRA was legally established as a Schedule
3A Public Entity in terms of the PFMA, 1999 (Act 1 of
1999) to fulfill specific responsibilities on behalf of national
government (National Treasury, 2015). As a Schedule 3A Public
Entity SAHPRA is separate juristic person outside of the
National Department of Health accountable for sound corporate
governance practices and adherence to compliance codes in
terms of relevant legislation, financial regulations, directives,
policies and procedures (National Treasury, 2015).
In October 2017 the Minister of Health, Aaron Motsoaledi,
announced the appointment of 15 SAHPRA Board members.
The Board members are appointed to serve for a period of 3
years under the leadership of Professor Helen Rees, the outgoing
Chairperson of the MCC and the first Chairperson of the
SAHPRA Board. In contrast to the MCC the SAHPRA Board
has full operational autonomy and accountability. Through the
Board the Authority is accountable to the Minister of Health
(Republic of South Africa, 2017). The SAHPRA Board after
consultation with the Minister of Health must appoint a suitably
qualified person as the CEO of the Authority (Republic of
South Africa, 2017). The CEO is accountable to and reports
to the SAHPRA Board and is responsible for the general
administration of the Authority and for the carrying out of any
functions assigned to the Authority (Republic of South Africa,
2017). The organizational structure of SAHPRA is depicted in
Figure 3 (South African Health Products Regulatory Authority
[SAHPRA], 2016). The four Directorates depicted in Figure 1
will be replaced by five programs responsible for performing
the regulatory activities of the Authority. In order to ensure
continuity transitional arrangements have been put in place for
the expert committees to continue providing scientific expertise
and support. A Regulatory Advisory/Oversight Committee for
medicines and medical devices has been appointed by the CEO in
consultation with the SAHPRA Board to investigate and report
to the Authority on any matter within its purview in terms of
Medicines and Related Substances Act, 1965 (Act 101 of 1965).
The SAHPRA Board may appoint one or more committees
from among its members to assist it with the performance
of its functions and has appointed a TORS Committee with
investigation into the backlog in application for registrations as
part of its remit.
“The legislative mandate of SAHPRA is derived from the
Constitution of the Republic of South Africa, 1996 which
places obligations on the state to progressively realize socio-
economic rights including access to health care as well as the
National Health Act, 2003 (Act 61) and the Medicines and
Related Substances Act, 1965 (Act 101 of 1965). According to
the Medicines and Related Substances Act, 1965 (Act 101 of
1965), “SAHPRA’s obligations include ensuring public protection,
ensuring transparency and accountability in its operations and
being responsive to the regulatory environment” (South African
Health Products Regulatory Authority [SAHPRA], 2016).
The functions of the Authority are defined in Section 2B of the
Medicines and Related Substances Act, 1965 (Act 101 of 1965).
The Authority must, in order to achieve its objectives, ensure that
the:
• “Evaluation or assessment and registration of medicines
and medical devices, is efficient, effective and ethical and
that registered medical products meet the defined standards
of quality, safety, efficacy, and performance;
• Process of evaluating or assessing and registering medicines
and medical devices is transparent, fair, objective and
concluded timeously;
• Medicines and medical devices are re-evaluated or
reassessed and monitored periodically;
• Existing and new adverse events, interactions and
information with regard to post-marketing surveillance
and vigilance are monitored, analyzed and acted upon;
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FIGURE 3 | Transitional organizational structure of the South African Health Products Regulatory Authority.
• Compliance with existing legislation is being promoted
and controlled through a process of active inspection and
investigation; and
• Clinical trial protocols are assessed according to prescribed
ethical and professional criteria and defined standards”
(Republic of South Africa, 2017).
Political will and leadership have seen the efforts for an
improved regulatory landscape in South Africa come to fruition
as the evolving NRA strives toward an effective and efficient
regulatory authority. The key operational differences between
the MCC and SAHPRA are highlighted in Table 3. The
mandate of SAHPRA has been extended to include medical
devices and complementary medicines and the legislative
framework for reliance and recognition has been finalized. It is
anticipated that improvements to the other operational elements
listed in Table 3 will be realized with the establishment of
SAHPRA.
Extended Mandate
In the past the MCC was mandated to ensure regulatory oversight
of human and veterinary medicines. With the promulgation
of the amendments to the principal Act the mandate of the
Authority has been extended to include medical devices, ionizing
and non-ionizing radiation emitting devices, radioactive nuclides
and complementary medicines.
Challenges and Changes
Historically the MCC faced resource constraints as workloads
placed on the regulator steadily increased. As a result the
MCC became dependent on over-committed external expertise.
Evaluation structures which relied on external evaluators
lacked effective performance management contracts and did
not provide a sustainable mechanism for timely submission
TABLE 3 | Key Operational differences between Medicines Control Council and
South African Health Products Regulatory Authority.
Operational
element
MCC SAHPRA
Mandate Human and Veterinary
Medicines
Medical Devices and
Complementary
Medicines included
Organizational
structure
Under-resourced: Fully resourced:
Outsourced expertise In-house capacity
Harmonization
initiatives
Limited scope for
reliance mechanisms
Legal framework for
reliance mechanisms
Quality
management
system
Informal
implementation of QMS
Formal implementation
of QMS
Document
management
System
Paper-driven Electronic Document
Management
Systems-driven
Fee structure Collection of fees by
National Treasury
Retention of user-fees
Service delivery History of backlogs Improved timeliness
Stakeholder
relationships
Stretched industry
relationships
Transparency and
accountability
of evaluation reports. The regulatory functions mandated
to SAHPRA are people-dependent (South African Health
Products Regulatory Authority [SAHPRA], 2016). Adequate,
competent and motivated human capital plays a vital role in
ensuring organizational success (South African Health Products
Regulatory Authority [SAHPRA], 2016) “It is the intended goal
of SAHPRA to have an adequate number of staff with the
right skills mix, at the right level, available and employed in
appropriate positions within the organization” (South African
Health Products Regulatory Authority [SAHPRA], 2016). Efforts
Frontiers in Pharmacology | www.frontiersin.org 8 December 2018 | Volume 9 | Article 1407
fphar-09-01407 December 4, 2018 Time: 16:50 # 9
Keyter et al. The South African Regulatory System
to reform organizational structures within SAHPRA should be
prioritized to build and retain in-house scientific skills in order
to decrease over-reliance on external expertise.
Harmonization Initiatives
As an Authority mindful of limited resources and capacity
constraints the MCC had always recognized the value of
harmonization initiatives and had explored the possibility
of implementing reliance mechanisms. In the past the MCC
participated in regional collaboration initiatives such as the
ZaZiBoNa collaborative work-sharing process which aims
to harmonize regulatory efforts between regional NRAs.
Harmonization efforts may now be actively enforced as the
inclusion of Section 2B(2)(a) and 2B(2)(b) in the Medicines Act
provides a mandate for the Authority to liaise with and enter into
agreements with any other regulatory authorities or institutions
(Republic of South Africa, 2017).
The advantages of such regulatory relationships are offset
by a number of prerequisites including the assumption that
SAHPRA adopts internationally harmonized guidelines and
standards (South African Health Products Regulatory Authority
[SAHPRA], 2016), relevant memoranda of understanding and
confidentiality agreements are in place with reliable regulatory
authorities recognized by SAHPRA (Green Thompson, 2008),
that SAHPRA remains accountable for the health and safety
of the citizens of South Africa (South African Health Products
Regulatory Authority [SAHPRA], 2016), that some regulatory
decisions may be made based on the regulatory activities and/or
decisions made by other reliable authorities and recognized by
SAHPRA (South African Health Products Regulatory Authority
[SAHPRA], 2016) and that enhancing regulatory convergence
and participating in collaboration and work-sharing initiatives
will contribute toward a decreased regulatory burden and a
decreased workload on SAHPRA. SAHPRA will also have the
opportunity to make better use of the limited resources available
to improve post-marketing surveillance activities and will
contribute toward efforts to minimize duplication of regulatory
efforts (World Health Organization [WHO], 2003).
Quality Management System
The MCC has recognized the importance of formally
implementing quality measures throughout the agency in
order to ensure consistency, increase transparency and improve
efficiencies. In the past the MCC did not have a dedicated
Quality Management Unit, however, contingencies have
been put in place to establish such a unit. This unit will be
responsible for formalizing the implementation of the QMS for
the authority and for performing internal quality audits and for
implementing strategies geared for continuous improvement.
The implementation of a formalized QMS will ensure that
GRevPs are codified into policies and guidelines, regularly
monitored and subject to continuous improvement (World
Health Organization [WHO], 2016). Through the application of
a robust QMS underpinned by the drive to cultivate an integral
quality culture the regulatory performance and responsiveness of
SAHPRA will be enhanced.
Document Management System
“A regulatory authority must have an effective system of
tracking application assessment processes and decision-making;
these systems require an appropriate use of information
technology” (Hill and Johnson, 2004). The development of
an integrated information system, improvement of the current
ICT infrastructure and the use of an EDMS will be essential
for SAHPRA. Given the large volume of complex applications
submitted to the Authority and the need for optimal document
management it is critical that the Authority moves away from
the historically paper-driven processes of the MCC. It is the
intention of SAHPRA to implement an EDMS that can replace
the legacy systems currently in use. SIAMED, a software program
adopted from the WHO, is one such system that is used to
track and manage applications for registration of medicines. This
system has become outdated and will be phased out as electronic
systems capable of facilitating the electronic submission of
applications and robust document management functionalities
are introduced.
Fee Structure
The historical integration of the MCC into the operations of
the South African National Department of Health has not
served the MCC well as it worked toward ambitious goals of
improved regulatory performance without the financial support
required to establish a new regulatory authority that would be
a viable regulator of medical products, trusted and respected
by the pharmaceutical industry, civil society and patients
of the Republic (South African Health Products Regulatory
Authority [SAHPRA], 2016). The Act makes provision for
the Authority to levy fees for services rendered for example,
a fee may be charged for the evaluation and registration of
medical products. Fee structures vary significantly between
different regulatory authorities. Fees may be set arbitrarily,
they may be related to the cost of providing a service
or they may be scaled, commensurate with the amount of
data submitted and the time required for evaluation of the
data.
As SAHPRA develops its organization it is important to
consider its fee structure for its future sustainability. In view
of the current backlog and protracted review times it is vital
that there should be an increase in the resources (e.g., trained
staff and infrastructure) to ensure that the new authority achieve
its goal in bringing the review times in line with other mature
established authorities. Antrobus and Egerton-Warburton (2016)
have reported comparative figures on regulatory fees which
dramatically illustrate how South Africa fees lags behind several
comparable regulatory authorities and they have proposed how
to achieve financial sustainability with a carefully revised fee
structure. There are, of course, recent examples such as China
and Japan who have demonstrated that measured increase in
fees has translated into several fold increase in trained staff
and subsequently led to reduction in timelines (Antrobus and
Egerton-Warburton, 2016; Bujar et al., 2018).
The establishment of SAHPRA as a 3A Public Entity allows
for change in that the finances generated by the Authority
will be retained. This revenue structure is different to the past
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model that existed within the MCC whereby incoming fees were
collected by the National Treasury and channeled to central
government revenue. Although the Authority will be partially
funded from the national government funds a key deliverable
for SAHPRA will be to raise the required revenue to make the
Authority sustainable (South African Health Products Regulatory
Authority [SAHPRA], 2016). Suggestions to increase the fees
for services levied by the Authority may be a solution but this
will require significant improvements in regulatory efficiencies in
order to appease the demands and expectations of stakeholders.
Furthermore, an opportunity exists to generate more fees as the
mandate of the Authority is extended to include the regulation
of medical devices, complementary medicines and radiation
control (South African Health Products Regulatory Authority
[SAHPRA], 2016).
Service Delivery and Stakeholder
Relationships
“SAHPRA has an obligation to effectively implement a regulatory
framework that supports regulatory functions, enables the
objectives of the National Drug Policy and promotes the priority
goals of the National Department of Health” (South African
Health Products Regulatory Authority [SAHPRA], 2016). In
order to do so it is necessary to improve structures within the
Authority and advance the functions of the Authority to develop
an accessible regulatory service footprint (South African Health
Products Regulatory Authority [SAHPRA], 2016).
Recognition of SAHPRA as a sustainable-well functioning
regulatory system is a key feature of the strategic outcome
oriented goals for the Authority (South African Health Products
Regulatory Authority [SAHPRA], 2016). The effectiveness of
the regulatory systems developed, implemented and maintained
by SAHPRA must be periodically measured against GRevP
and pre-defined performance-based indicators (World Health
Organization [WHO], 2014b; South African Health Products
Regulatory Authority [SAHPRA], 2016). Global benchmarking of
the Authority against the indicators of the global benchmarking
tool developed by the WHO to evaluate and grade the maturity
level of the regulatory systems of NRAs will also provide
a measurement of the Authority’s performance in assuring
independent and competent oversight of medical products
in South Africa (World Health Organization [WHO], 2017).
Delivering on such regulatory performance objectives will
also provide a platform for building strong and sustainable
relationships with stakeholders with an emphasis on customer
satisfaction.
THE REGULATORY REVIEW PROCESS
IN SOUTH AFRICA: MODALITIES FOR
CHANGE
Through the amendment of the Medicines Act and the
establishment of SAHPRA a new era has dawned bringing about
new opportunities for regulatory reform and the possibility
to re-engineer outdated processes. Priority should be given to
addressing the inefficiencies of the current regulatory review
process through consideration of different types of product
review assessments used by NRAs worldwide in the review of
applications for registration of medicines namely the verification
review (type 1), an abridged review (type 2) and a full review (type
3) (McAuslane et al., 2009). SAHPRA may decide to continue
with the current approach used historically by the MCC whereby
a type 3 full independent assessment of quality, efficacy, and
safety data is performed in the review of all applications for
registration, however, it may be prudent to consider applying a
risk-based assessment for those applications already reviewed by
reference agencies in order to ensure timely access of medicines
and medical devices.
Risk-Based Approach to the Evaluation
of Medicines
Management of limited resources may be improved through
the application of a risk-based approach to medical product
regulation. This approach allows regulators to direct the
appropriate resources required to those medical products that
pose a greater risk to patients. The amount of resources applied
by the regulator should be commensurate with the level of
risk of a medical product and should be applied only to the
extent necessary to ensure patient safety (Therapeutic Goods
Administration [TGA], 2018). Many NRAs including resourced
and mature regulatory authorities make use of FRPs for the
assessment of applications for registration of medicines (Liberti,
2018). Primary FRPs are used to decrease review times of
medicines that have not been reviewed by another NRA and
that are not dependent on the review/decision made by another
NRA for example products for unmet needs and oncology
(Liberti, 2018). Secondary FRPs are used by NRAs to decrease
review times of medicines that have been reviewed by another
recognized NRA (Liberti, 2018). The regulatory decision can
be expedited through reliance on or recognition of a prior
review/decision by another NRA (Liberti, 2018). FRPs inform
risk-stratification approaches to the assessment of applications
for registration of medicines.
Should SAHPRA wish to apply such risk-based approaches the
following types of review may be considered (Green Thompson,
2008). The first is a full review of the complete quality, pre-
clinical and clinical data applicable to medicines that have not
been reviewed/approved by an NRA recognized by SAHPRA
(Green Thompson, 2008). The second is an abridged review
applicable to a medicine that has been reviewed/approved by
one recognized NRA (World Health Assembly, 2014). Similar
to the Mutual Recognition Procedure used in the European
Union the abridged review makes use of the evaluation report
and the regulatory decision of a recognized NRA to guide the
evaluation of the medicine by SAHPRA (Green Thompson, 2008;
Liberti, 2018). The third is the verification review that may be
used to evaluate a medicine that has been approved by at least
two recognized NRAs (Green Thompson, 2008). Through this
review the product is validated for conformance to the authorized
product specification (Pharasi and Banoo, 2015). The fourth
is the evaluation of a dossier for a generic medicine (Green
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Thompson, 2008). The generic medicine should be approved
by at least one recognized NRA and should correspond to the
reference product (with the same dosage form and strength)
registered by SAHPRA (Green Thompson, 2008).
Despite the type of review chosen for any given submission
SAHPRA may insist that a full dossier consisting of complete
quality, pre-clinical and clinical data is submitted upon
application for medicine registration. Although a full assessment
of the complete data may not be performed having the full
dossier available on file will be advantageous for purposes
of future reference or for post-market surveillance activities.
A letter of intent to submit an application for registration of a
medicine would be required to allow the regulator to adequately
plan and allocate the necessary resources required to evaluate
upcoming submissions. Through this process, the regulator may
also anticipate whether specific expertise would be required in the
assessment of the application and may be afforded the advantage
of recruiting such expertise in advance thus circumventing
unnecessary delays in the review process. This risk-based
approach could be successfully applied provided that agreements
are in place between SAHPRA and recognized NRAs to ensure
that information pertaining to medicine assessment reports, post-
marketing surveillance and post-marketing variations and/or
amendments is easily shared and disclosed. As this system
develops SAHPRA may consider introducing improved processes
based on similar risk-stratification processes to address the
submission of applications for variations and amendments to
registered dossiers (Green Thompson, 2008). In re-designing
the regulatory review process it would be prudent to consider
the application of an appropriate framework for benefit-
risk assessment to facilitate the evaluation of the benefit-risk
balance of medicines prior to registration (Green Thompson,
2008; Leong et al., 2015). The implementation of GRPs and
GRevP (South African Health Products Regulatory Authority
[SAHPRA], 2016) and quality decision-making principles are
also recommended with a view to reinforce transparent decision-
making processes. Therefore, the application of risk-stratification
approaches and FRPs would be an advantage when considered
in line with the recommendations of the WHO (Ward, 2014;
World Health Organization [WHO], 2014b). It remains to be
seen if these proposed initiatives will be implemented by the new
organization.
Monitoring and Measuring
In the current model there is no target for overall approval
time of applications for registration and no targets for the key
review milestones. The targets for overall approval time and key
review milestones need to be identified, codified into policy and
guidelines, recorded, measured and monitored. Figure 4 provides
a generic figure of individual milestones that have been used by
other regulatory authorities and that may be considered for use
within SAHPRA.
Appropriate systems and resources need to be put in place to
support the accurate tracking of the overall approval times and
key milestones in the regulatory review process. Administrative
and technical screening time, queuing time prior to review
and clock stops, measuring the time with applicants, must be
FIGURE 4 | Benchmarking milestones currently utilized by regulatory
authorities.
recorded and monitored. The metrics collection process must be
strengthened in order to allow measurement and improvement
of SAHPRA regulatory performance.
With accountability and transparency being a focus within
the medicine regulatory landscape in South Africa, SAHPRA
has to be cognizant of the past administrative injustices
and take ownership of its performance. SAHPRA targets for
regulatory review must be communicated to all stakeholders
and it must be held responsible for meeting its obligations
in terms of such targets and demonstrate accountability to
parliament, to the public, to the industry and to all relevant
stakeholders (Green Thompson, 2008). Furthermore, SAHPRA
should undertake to employ the basic principles of administrative
justice within the routine practices and activities of the Authority
(Green Thompson, 2008). Providing written reasons to support
regulatory decisions made by the Authority could be one
such practice that may support legal certainty and contribute
to enhanced regulatory efficiencies and transparency (Green
Thompson, 2008). Quid pro quo provisions to relieve applicants
of consequences of regulatory under-performance may also need
to be considered (Green Thompson, 2008).
KEY RECOMMENDATIONS FOR A NEW
REGULATORY ENVIRONMENT
In order to ensure the full potential of the new regulatory
environment in South Africa the following recommendations are
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considered to be fundamental in underpinning the success of
SAHPRA:
Quality Management System
Establishment of such a system would help to safeguard
accountability, consistency and transparency of SAHPRA and
streamline the implementation of GRP and GRevP including
quality decision-making practices and benefit-risk assessment.
Measuring and Monitoring
This will ensure the measurement and improvement of regulatory
performance, targets for overall approval time and key review
milestones. Consequently, this will lead to the implementation
of appropriate systems for and a culture of accurate metrics
collection and measurement of key performance indicators and
their continuous improvement.
Risk-Based Approach to the Evaluation
of Medical Products
This will help to implement the appropriate allocation of
resources, codify the use of FRPs in policy and culture, apply
a risk-based approach commensurate with the product’s risk to
patients and apply increased resources for pharmacovigilance
activities and to support the reliance and recognition of reference
agencies.
Training and Skills Development of
Regulatory Expert Reviewers
Under the new SAHPRA initiative the review will be carried
out by internal staff and as such there needs to be a structured
program for the provision of ongoing training and skills
development of regulatory reviewers (scientists, pharmacists,
pharmacologists, and medical doctors).
The SAHPRA backlog clearance strategy requires that
additional capacity and efforts have been made to recruit
experienced reviewers to assist in this regard. There may be
much value added in considering the possibility of establishing
concomitant mentorship programs through which internal staff
may benefit from the proposed “apprentice-orientated” learning
opportunities that exist through the rollout of the backlog
clearance strategy.
Establishment of an Expert Advisory
Committee
By establishing an expert advisory committee, this could be of
value to support the regulatory reviewers as well as advise the
industry on best practices and providing feedback on the quality
of the submitted dossier.
CONCLUSION
The purpose of this review was to provide insight into the
history of the enabling legislation and expert reviews and
recommendations for regulatory reform that have given rise to
a new regulatory regime in South Africa. Many key opportunities
and modalities for change have been identified and it is evident
that re-enforcement of strategies to address inadequate financial
and human resources, stakeholder relationships, paper-driven
document management systems, service delivery and regulatory
review processes, need to be considered in order to strengthen
the regulatory systems in South Africa. With time and active
leadership from the SAHPRA Board together with the SAHPRA
CEO and the management team it is hoped that the re-engineered
strategies and processes, planned for implementation will serve to
enhance the regulatory landscape in South Africa.
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